Tigermed (3347.HK) From stabilization to growth, riding the wave of the Clinical CRO rebound; Upgrade A-share to Buy, Initiate H at Buy 13 October 2025 | 11:41PM HKT Equity Research | 3347.HK | 12m Price Target: HK$62.10 | Price: HK$42.70 | Upside: 45.4% | | --- | --- | --- | --- | | 300347.SZ | 12m Price Target: Rmb77.10 | Price: Rmb54.35 | Upside: 41.9% | We upgrade Tigermed (A) to Buy (from Neutral) and initiate the H share at Buy. As a leading domestic clinical CRO, Tigermed is well-positioned to benefi ...